טוען...
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
BACKGROUND: Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recommended at transplantation and non‐depleting interleukin‐2 receptor monoclonal antibodies (IL2Ra) are considered first line. It is suggested that recipients a...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2017
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6464766/ https://ncbi.nlm.nih.gov/pubmed/28073178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004759.pub2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|